Daiichi Sankyo Announces Write-off Loss on Trade Rights Related to consolidated subsidiary Plexxikon Inc.’s Anticancer Agent Zelboraf

Tokyo, Japan (April 28, 2015) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it will book an write-off loss on trade rights related to consolidated subsidiary Plexxikon Inc.’s anticancer agent Zelboraf. Details are as follows.

1. Details of write-off loss
   (1) Date of loss
       April 28, 2015
   (2) Reason for loss
       A decision was made to post an write-off loss on trade rights related to anticancer agent Zelboraf, owned by Plexxikon Inc., a consolidated subsidiary of Daiichi Sankyo, based on an examination of future recoverability following an observable decline in profitability.
   (3) Impact on consolidated financial results
       Daiichi Sankyo will book an write-off loss of ¥35 billion under cost of sales in the consolidated financial results for fiscal 2014 (IFRS).

2. Outline of subsidiary
   Company name: Plexxikon Inc.
   Location: 91 Bolivar Drive, Berkeley, CA 94710, USA
   Representative: Gideon Bollag, Ph.D., Chief Executive Officer
   Business description: Research and development focused on cancer, inflammation, cardio-renal disease, and the central nervous system
   Paid-in-capital: US $1.00